Functional Brands
Manufactures Kirkman supplements and extends them into prenatal and telehealth wellness offerings.
Something off on this page? Send us feedback.
Profile
Manufactures Kirkman and P2i over-the-counter supplements and sells through wholesale, practitioner, international-distributor, e-commerce, and direct channels. Tru2u.health adds outsourced telehealth and medication-based wellness services, while North America supplies most revenue and FDA, FTC, and state healthcare rules shape operations.
Manufactures and distributes over-the-counter nutraceutical supplements through the Kirkman division, including vitamins, probiotics, enzymes, amino acids, fatty acids, immune-support products, and specialty formulas. P2i by Kirkman focuses on prenatal vitamins, while Tru2u.health combines the supplement portfolio with outsourced telehealth support and medication-based wellness programs.
Kirkman products are made at an FDA-registered, cGMP-certified facility in Lake Oswego, with testing of incoming ingredients and finished batches. Sales reach consumers and practitioners through company websites, Amazon, U.S. wholesalers, pharmacies, and distributors serving international markets. North America generates most sales.
Operations depend on supplement demand, retailer and distributor relationships, imported inputs, quality controls, and FDA and FTC regulation. Tru2u.health also depends on CareValidate and compliance with state telehealth and prescribing requirements. Hemp-derived product lines have been discontinued.
Company facts
Key statistics
Year to date −97.5% · Average volume (30d) 296.3K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 17, 2026Q2 FY26 | — | −$0.06 | — | — | $1.9M | — | +15.40% |
| Aug 14, 2026Q2 FY26 | — | −$0.06 | — | — | $1.9M | — | −8.70% |
| Aug 13, 2026Q2 FY26 | — | −$0.06 | — | — | $1.9M | — | +12.20% |
| May 15, 2026Q1 FY26 | — | −$0.36 | — | — | $1.6M | — | −13.75% |
Financial highlights
| 9 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.6M | $1.8M | $1.7M | $1.5M | $1.6M | $1.9M | |
| Gross profit | $866.8K | $968.1K | $978.4K | $670.8K | $961.1K | $1.1M | |
| Operating income | −$32.1K | −$155.4K | −$78.3K | −$1.1M | −$682.8K | −$1.3M | |
| Net income | −$126.8K | −$226.1K | $259.0K | $852.3K | −$7.0M | −$2.6M | |
| Diluted EPS | −$0.02 | −$0.03 | $0.04 | $0.01 | −$0.08 | −$0.06 | |
| Gross margin | 54.5% | 52.8% | 57.7% | 44.9% | 58.4% | 59.9% | |
| Operating margin | -2.0% | -8.5% | -4.6% | -75.8% | -41.5% | -70.6% |
Fiscal years (4-quarter sums)FY25 $6.6M
Balance sheet, Jun 30, 2026Cash & short-term investments $352.1K · Total debt $1.7M · Total assets $6.5M · Shareholders' equity −$3.0M
Dividends
No dividends on record.
Ownership
Shares outstanding 42.21M · Float 40.90M
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Leonite Fund I, LP | 2.29M | 8.80% | 13G | May 13, 2026 |
| Eric Jon Gripentrog · director, officer: Chief Executive Officer | 710.9K | 1.68% | Form 4 | Dec 4, 2025 |
| Geode Capital Management, LLC | 178.0K | 0.42% | 13F | May 15, 2026 |
| HRT Financial LP | 72.9K | 0.17% | 13F | May 14, 2026 |
| Citadel Advisors LLC | 42.5K | 0.10% | 13F | May 15, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
Not reported.